The Next Industrial Revolution: Computational Biology & Bioplatforms

NFX Bio: Investing in Scientist-Founders from the Very Beginning with Omri Amirav-Drory

A Mammoth Becomes A Unicorn: Inside a Scientist-Founder’s Journey from Pre-Seed to Series D

Why C2i is the World’s First Platform for Cancer Intelligence

The Race to 150

Why NFX Invested in TwoStep Therapeutics: One Elegant Platform Targeting 90% of Cancers

How VCs Become Assholes

The Business Case for Longevity

A Scientific Approach To Your Company (And Your Life)

What I Wish I Knew as a Scientist-Founder

A Scientific Approach to VC

The Future of Longevity: The Battle Against Human Aging (An NFX Documentary)

Why NFX Invested in Mana Bio: The TechBio Platform Using AI for Better Drug Delivery

The Future of Longevity: Keeping Healthy People Healthy

The 3 Waves of AI in Bio

Maximizing TechBio Deal Potential: Platform vs. Asset Deals

Deal or Die: Your 3-Part Guide to Business Development in TechBio

Tech Founders, Don’t Be Afraid of Bio

What Doesn’t Kill You, Mutates And Tries Again

From Sick Care to Health Care: Why We Need Longevity Startups

How to Prove Your TechBio Platform at Seed Stage

Why NFX Invested in Centivax: The TechBio Platform Developing Universal Vaccines

Academia or Startup? A Decision Matrix for Future Scientist-Founders

The Golden Ratio: Navigating East Coast v. West Coast in TechBio Investing